PENNSYLVANIA LEGISLATURE PASSES ONE-LINE Rx FORM BILL
Executive Summary
PENNSYLVANIA LEGISLATURE PASSES ONE-LINE Rx FORM BILL, which was forwarded on Dec. 1 to Governor Casey for signature. The state legislation requires prescribers who wish to block generic substitution to write "brand necessary" or "brand medically necessary" on prescription forms. Pennsylvania's previous generic substitution law provided for a two-line form; prescribers signed on the left line to block substitution. The legislation reportedly had the support of the governor. The bill was adopted by the Senate by a 47-2 vote on Nov. 29 and by the House with a 185-6 margin on Nov. 30. The measure will become state law regardless of whether Casey signs it within a 30-day limit. Among minor amendments that distinguish the final bill from a version passed by the House of Representatives in April, one change delays the effective date from 60 days after enactment to July 1, 1989. Estimates of the potential savings for the state's PACE elderly assistance program because of the bill range from $30 mil. to $60 mil. per year. More than two dozen states now have generic substitution laws providing for a one-line prescription form.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth